Velocity Clinical Research, Medford
Velocity Clinical Research, Medford
Medford, Oregon, United States9 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK) | Plaque Psoriasis | Recruiting | Phase 3 | 2026-09-22 | NCT07116967 | |
| Long-term Follow-up Study to Evaluate Safety and Immunogenicity of CHIKV VLP Single or Booster Vaccination | Alphavirus infectious disease, Infections, Mosquito-Borne Diseases, RNA Virus Infections, Togaviridae infectious disease, arbovirus infection, chikungunya, vector-borne disease, viral infectious disease | Active, not recruiting | Phase 3 | 2026-08-07 | NCT06007183 | |
| A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia | Body Weight, Dyslipidemias, Hypercholesterolemia, Lipid Metabolism Disorders, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, hyperlipidemia, metabolic disease, nutritional disorder, obesity disorder, overnutrition | Recruiting | Phase 2 | 2026-07-22 | NCT07477704 | |
| Efficacy and Safety of NVX-CoV2705 | COVID-19, Coronaviridae Infections, Infections, Nidovirales infectious disease, Orthocoronavirinae infectious disease, RNA Virus Infections, lung disorder, pneumonia, respiratory system disorder, respiratory tract infectious disorder, viral infectious disease, viral pneumonia | Active, not recruiting | Phase 4 | 2026-05-08 | NCT07086222 | |
| A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hypersensitivity, Immediate, Skin Diseases, Eczematous, Skin and Connective Tissue Diseases, atopic eczema, dermatitis, hereditary disease, hereditary skin disorder, immune system disorder, skin disorder | Recruiting | Phase 2 | 2026-05-04 | NCT05995964 | |
| A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age | COVID-19, Coronaviridae Infections, Infections, Nidovirales infectious disease, Orthocoronavirinae infectious disease, RNA Virus Infections, lung disorder, pneumonia, respiratory system disorder, respiratory tract infectious disorder, viral infectious disease, viral pneumonia | Active, not recruiting | Phase 3 | 2026-04-13 | NCT07300839 | |
| Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE) | Body Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, nutritional disorder, obesity disorder, overnutrition | Active, not recruiting | Phase 4 | 2026-03-31 | NCT06098079 | |
| Study to Evaluate the Efficacy, Immunogenicity, and Safety of RSVpreF in Adults. | Lower Respiratory Tract Illness | Active, not recruiting | Phase 3 | 2026-01-28 | NCT05035212 | |
| A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3) | Alzheimer disease, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy | Active, not recruiting | Phase 3 | 2026-01-21 | NCT05026866 |